RVTY
Revvity, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$131.40
+0.59%Year over year
Reported trailing growth
- Revenue
- +4.1%
- EBITDA
- -6.7%
- EBIT
- -9.8%
- EPS
- -11.0%
- Free cash flow
- +11.2%
- Operating cash flow
- +7.6%
Forward estimates
Based on analyst estimates
- Revenue
- +0.3%
- EBITDA
- +78.0%
- EPS
- +168.5%
Three-year CAGR
- Revenue
- -4.8%
- EBITDA
- -17.6%
- EBIT
- -23.0%
- Net income
- -24.8%
- EPS
- -22.7%
- Free cash flow
- -5.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026